Clinical trials: Osteogenesis Imperfecta
Osteogenesis Imperfecta
Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis Imperfecta
This research study aims to evaluate the effect of a 6-month adapted physical activity program (APA) on the endurance capacities (evaluated as the maximum oxygen consumption [VO2 peak]) of children and adolescents with…
- Trial name
- BONeMOVE (NCT05927389)
- Testing
- Adapted Physical Activity program
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Osteogenesis Imperfecta
Study of Osteogenesis Imperfecta Tendon
Osteogenesis imperfecta (OI) is a rare genetic disease due to a mutation in one of the genes encoding either type I collagen or a protein involved in its synthesis. This leads to bone fragility with fractures and deformities.
- Trial name
- SOIT (NCT06065111)
- Testing
- study tendon damage in osteogenesis imperfecta patients
- Where
- Belgium
- Volunteers
- 130 people
- Sponsor
- Université Catholique de Louvain
Osteogenesis Imperfecta
Bisphosphonate Treatment of Osteogenesis Imperfecta
The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.
- Trial name
- NCT00063479
- Testing
- Zoledronic Acid
- Where
- 10 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Osteogenesis Imperfecta
Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
Overall Objective: To test the hypothesis that oral vitamin D supplementation at higher than currently prescribed doses has a beneficial effect on the skeleton of young patients with osteogenesis imperfecta (OI).
- Trial name
- NCT01713231
- Testing
- standard-dose vitamin D (400IU per day), high-dose vitamin D (2000 IU per day)
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Louis-Nicolas Veilleux Ph.D.
Osteogenesis Imperfecta
Tranexamic Acid During Telescoping Nail Application In Osteogenesis Imperfecta
The aim of this study is to assess the effective of intraoperative use of tranexamic acid in reducing blood loss during telescoping nail application in cases of osteogenesis imperfecta.
- Trial name
- NCT05321199
- Testing
- Tranexamic acid
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assiut University
Multiple Osteochondroma, Osteogenesis Imperfecta
NGS Strategy Effectiveness in Molecular Diagnosis
The coming out of Next Generation Sequencing (NGS) technologies, with documented advantages and reduced costs respect to Sanger sequencing, has provided new appealing approaches to diagnostic testing.
- Trial name
- NCT03557567
- Testing
- NGS molecular screening
- Volunteers
- 400 people
- Sponsor
- Istituto Ortopedico Rizzoli
Osteogenesis Imperfecta
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
The primary objective of the study is to evaluate the effect of setrusumab vs intravenous bisphosphonates (IV-BP) on reduction in fracture rate, including morphometric vertebral fractures in pediatric participants.
- Trial name
- Cosmic (NCT05768854)
- Testing
- Bisphosphonate, Setrusumab
- Where
- 20 sites in United States, Brazil and 5 more
- Volunteers
- 69 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteogenesis Imperfecta
Post-market Observational Study on JTIN Telescopic Nail in Osteogenesis Imperfecta Pediatric Patients
This study has been planned as part of the Orthofix Srl post-market active surveillance plan for the collection of data on both the clinical performance and the safety profile of the JTIN.
- Trial name
- JTIN (NCT05612139)
- Testing
- JTIN implantation surgery
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Orthofix s.r.l.
Osteogenesis Imperfecta
e-Health Care Method for Patients With Osteogenesis Imperfecta (Tele OI)
This work seeks to formalize the association between the use of technology and the effective treatment of patients with Osteogenesis Imperfecta, which has not yet been explored in the literature; and aims to prove functional…
- Trial name
- Tele OI (NCT06555536)
- Testing
- Tele OI
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Paulo Humberto Mem Martendal Vallandro Costa
Osteogenesis Imperfecta
Urinary Biomarkers of OI Pathobiology
Osteogenesis imperfecta (OI) is a rare inherited disorder that causes bones to break easily. Individuals with osteogenesis imperfecta break bones often and may have other problems, including hearing loss, dental problems, pain…
- Trial name
- NCT02531087
- Where
- 7 sites in United States, Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Osteogenesis Imperfecta
Nutritional Interventional in Pediatric Patients With Osteogenesis Imperfecta
BACKGROUND: In several bone disorders, adequate calcium intake is a coadjuvant intervention to regular treatment. Osteogenesis imperfecta (OI) is a collagen disorder with a range of symptoms, ranging from fractures to minimum…
- Trial name
- NCT03841188
- Testing
- Nutritional orientation
- Where
- Brazil
- Volunteers
- 52 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Osteogenesis Imperfecta
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
This protocol was a prospective, Phase I study of allogeneic bone marrow transplantation (BMT) as the primary therapy for Osteogenesis Imperfecta Types II and III.
- Trial name
- NCT00705120
- Testing
- Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- St. Jude Children's Research Hospital
Brittle Bone Disease
Preventive Fixation of Lower Limbs in Osteogenesis Imperfecta (Brittle Bone Disease) With the Highlight of the Fassier-Duval
Osteogenesis imperfecta (or brittle bone disease) is a rare genetic disease characterized by fragile bone and a low mass ossue, secondary to abnormal collagen synthesis. This is a real congenital osteoporosis.
- Trial name
- Fassier-Duval (NCT02868294)
- Testing
- Fassier-Duval Nail
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3.
- Trial name
- NCT05559801
- Testing
- Bone marrow-derived mesenchymal stromal cells (MSCs)
- Volunteers
- 12 people
- Sponsor
- Emory University
Bone Disease, Metabolic
Diagnosis of Osteogenesis Imperfecta in Children
The study will be conducted at Assiut university children hospital and it will include patients with history of repeated fractures due to mild or irrelevant trauma.
- Trial name
- NCT03169192
- Testing
- Zoledronic Acid
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Osteogenesis Imperfecta (OI)
Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
To evaluate long-term safety of denosumab in children/young adults with pediatric osteogenesis imperfecta (OI) who completed the prior study 20130173 (NCT02352753).
- Trial name
- NCT03638128
- Testing
- Denosumab, Alternative osteoporosis medications
- Where
- 22 sites in United States, Australia and 10 more
- Volunteers
- 75 people
- Sponsor
- Amgen
Osteogenesis Imperfecta
Setrusumab vs Placebo for Osteogenesis Imperfecta
The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in fracture rate.
- Trial name
- Orbit (NCT05125809)
- Testing
- Setrusumab
- Where
- 43 sites in United States, Australia and 9 more
- Volunteers
- 183 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteogenesis Imperfecta
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
Children with Osteogenesis Imperfecta (OI) have bone pain, low bone mass and fractures. There are no approved drugs for the treatment of OI in children, even though some intravenous (IV) bisphosphonates are used off-label in some…
- Trial name
- NCT00106028
- Testing
- risedronate sodium (Actonel)
- Where
- 20 sites in United States, Australia and 11 more
- Volunteers
- 143 people
- Sponsor
- Warner Chilcott
Duchenne / Becker Muscular Dystrophy, Osteogenesis Imperfecta (OI)
Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders
The primary aim of this observational study is to investigate specific aspects of social cognition in dystrophinopathies. Body awareness, interpersonal distance and emotional processing will be measured in a sample of patients…
- Conditions
- Duchenne / Becker Muscular Dystrophy, Osteogenesis Imperfecta (OI), Social Cognition
- Trial name
- NCT06874166
- Testing
- Electroencephalography (EEG), Social Cognition Tasks
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- IRCCS Eugenio Medea
Osteogenesis Imperfecta
Dental Malocclusion and Craniofacial Development in OI
Osteogenesis imperfecta (OI) is a rare inherited disorder that causes bones to break easily. Individuals with osteogenesis imperfecta break bones often and may have other problems, including hearing loss and pain and difficulty…
- Trial name
- NCT02934451
- Where
- 3 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Baylor College of Medicine